All In Biotech

Drug Trial Radar · NCT05044819

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

Last checked: Nov 20, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

154

Actual

Start

Jul 7, 2021

Primary completion

Aug 1, 2027

Study completion Mar 31, 2028

Sponsor

Lead sponsor
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
Sponsor type
Industry
Collaborators
Jazz Pharmaceuticals Research UK Limited
First posted
Sep 16, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will monitor for potential chronic liver injury and liver fibrosis, in participants treated with cannabidiol oral solution.

Conditions

  • Lennox Gastaut Syndrome
  • Dravet Syndrome
  • Tuberous Sclerosis Complex

Interventions

  • CannabidiolDrug

    Oral Cannabidiol solution 100 mg/mL

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Liver Fibrosis and Evaluable Fibrotic Changes as Determined and Assessed by an Independent Adjudication CommitteeTime frame: Screening, Day 365, Day 730, Day 1095, Day 1460, and Day 1825

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Little Rock, Arkansas

  • Clinical Trial Site

    Downey, California

  • Clinical Trial Site

    Long Beach, California

  • Clinical Trial Site

    Sacramento, California

  • Clinical Trial Site

    Miami, Florida

  • Clinical Trial Site

    Miami, Florida

  • Clinical Trial Site

    Orlando, Florida

  • Clinical Trial Site

    Tampa, Florida

  • Clinical Trial Site

    Augusta, Georgia

  • Clinical Trial Site

    Wichita, Kansas

  • Clinical Trial Site

    Lexington, Kentucky

  • Clinical Trial Site

    Baltimore, Maryland

  • Clinical Trial Site

    Boston, Massachusetts

  • Clinical Trial Site

    New Brunswick, New Jersey

  • Clinical Trial Site

    New York, New York

  • Clinical Trial Site

    Charlotte, North Carolina

  • Clinical Trial Site

    Durham, North Carolina

  • Clinical Trial Site

    Cincinnati, Ohio

  • Clinical Trial Site

    Oklahoma City, Oklahoma

  • Clinical Trial Site

    Philadelphia, Pennsylvania

  • Clinical Trial Site

    Charleston, South Carolina

  • Clinical Trial Site

    Austin, Texas

  • Clinical Trial Site

    Dallas, Texas

  • Clinical Trial Site

    Houston, Texas

  • Clinical Trial Site

    Round Rock, Texas

  • Clinical Trial Site

    Winchester, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.